- Home
- ARWR vs DINO Comparison
ARWR vs DINO Comparison
Compare ARWR & DINO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARWR | DINO |
|---|---|---|
| Founded | 2003 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 12.9B |
| IPO Year | 2009 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ARWR | DINO |
|---|---|---|
| Price | $59.98 | $112.19 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 17 |
| Target Price | $107.71 | ★ $122.81 |
| AVG Volume (30 Days) | 1.7M | ★ 2.2M |
| Earning Date | 11-24-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 1.83% |
| EPS Growth | 99.80 | ★ 238.46 |
| EPS | N/A | ★ 19.75 |
| Revenue | ★ $16,142,321.00 | N/A |
| Revenue This Year | N/A | $35.99 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.82 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.06 | $45.71 |
| 52 Week High | $95.49 | $129.37 |
Technical Indicators
Market Signals| Indicator | ARWR | DINO |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | 43.25 |
| Support Level | $54.93 | $103.00 |
| Resistance Level | $66.37 | $118.39 |
| Average True Range (ATR) | 2.22 | 5.28 |
| MACD | 0.91 | -2.04 |
| Stochastic Oscillator | 71.90 | 15.76 |
Price Performance
Historical ComparisonAbout ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
About DINO HF Sinclair Corporation
HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 350 distributors and 1,700 wholesale branded sites across 30 states. It also owns and operates 4,500 miles of petroleum product pipelines and terminals principally in the southwestern United States.